Spasticity can be a serious problem for victims of cerebral and spinal injury. It can interfere with programs of rehabilitation and adequate self-care. Oral antispasticity drugs can only achieve slight modulating effects and side effects are common. An alternative to dorsal rhizotomy, tenotomy, and epidural neurostimulation is long-term intrathecal delivery of baclofen with a pump. Due to the proximity of the medication to the site of action, a better effect on spasticity can be achieved with extremely low doses (30 &mu;gr). Many side effects are reduced, such as the gastrointestinal disturbances of nausea and constipation, drowsiness, fatigue, weakness, tiredness, and/or, with an oral overdose, depression of the central nervous system with coma and respiratory depression. In the Department of Neurosurgery at the University Medical Center in Gottingen, intrathecal medicine pumps have been implanted in 70 patients with spasticity resulting from spinal or cerebral lesions, with baclofen doses of between 30 and 1200 &mu;gr/day. From our experience, long-term intrathecal treatment with baclofen for most forms of spinal and cerebral spasticity is effective and helpful. The possibility of using the treatment for patients receiving ambulatory care in neurologic centers and the possible reduction of oral antispasticity agents are additional advantages of the method.
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The intrathecal application of haclofen is an alternative to these destructive operations. It was first attempted by American and German investigational teams in 1985 (1, 6) . In a number of different experimental studies, the effect of intrathecal baclofen in interrupting polysynaptic segmental reflexes has been demonstrated. Long-term experiments on animals and in vitro studies did not detect toxic effects of this medication in intrathecal treatment (5, 6, 9) .
Materials and Methods
The principle of the treatment method presented here is the use of a commercially available medication pump system that can deliver a continuous dosage of baclofen (Strato/Infusaid, Norwood, MA). A catheter and a port system are implanted while the patient is in the 90° lateral recumbent position. Two catheters are connected through an auxiliary incision in the patient's side. Using a daily bolus injection of baclofcn, the patient's sensitivity and optimal daily dosage are determined. Upon completion of this testing, the port is replaced with a pump. The pump's gas chamber is compressed by the baclofen solution, which is injected into the pump. Under the influence of body heat, the chamber expands, successively releasing the baclofen through a capillary tube that is several meters long. Consequently, overdoses are practically impossible. Through the side port of the pump, the b~iclofen solution can be replenished by bolus injections, or contrast medium xray monitoring can be performed. No major changes in the life style of the patient are required after implantation of the pump.
Results
In the Department of Neurosurgery at the University Medical Center in Gottingen, 75 patients were evaluated for treatment with intrathecal baclofen, and 70 of the 75 have been treated. (Figure 1 ). Due to the proximity of the release of baclofen to the site of action, it was possible to obtain effective reduction of spasticity with extremely low haclofen doses during a fivc-year observation period. In the course of this period, 52 patients had no complications. Nine patients were reoperated because of complications at the insertion site, such as catheter dislocation, pump malfunction, and wound infection. In six patients the pump was removed after an extremely good treatment response that again allowed the use of ural bacloren. In three patients it was necessary to terminate the treatment and remove the pump due to side effects (Figure 2 ).
Initially it was necessary to regularly increase the baclofen dosage. Later, after about six months, the daily doses remained constant; because of this it was assumed that tolerance develops very slowly.
Functional scores for the upper and lower extremities and the trunk showed considerable improvement. Bed-ridden patients were again able to use their wheelchairs. Physiotherapy programs were more easily carried out and more intensively employed. Bladder control was improved, but defecation and sexual function remained unchanged. The neurologic deficit was not changed by the treatment.
Side effects of oral baclofen, such as poor gastrointestinal tolerance, fatigue, and central nervous system depression, were reduced. The method should be employed only under the following conditions: (1) when all measures for the treatment of the primary disease have been e·chausted; (2) Long-term use of intrathecal baclofen is effective in treating spasticity from most causes, including spinal cord injury, multiple sclerosis, and cerehrall injury. Relief of spasticity improves the effect of rehabilitation programs (Figure 3) (7) . A major advantage is the It)&dquo;, haclofen dose, which on average is only 1/100 of the ural dose. The operative implantation is surgically simple; the pump system has an inexhaustihle energy source and requires refilling every four to seven weeks. 
